지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 291 - 303 (13page)
- DOI
- 10.4143/crt.2022.017
이용수
초록· 키워드
오류제보하기
Purpose Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).Materials and Methods After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.Results Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.Conclusion Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Cancer Research and Treatment
2024 .07
-
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Cancer Research and Treatment
2024 .01
-
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
Cancer Research and Treatment
2022 .04
-
Clinical Circulating Tumor DNA Testing for Precision Oncology
Cancer Research and Treatment
2023 .04
-
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
Cancer Research and Treatment
2020 .01
-
혈중 순환 종양 DNA 분석 임상 적용 가이드라인 소개
Laboratory Medicine Online
2024 .07
-
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cancer Research and Treatment
2019 .01
-
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays
Annals of Laboratory Medicine
2024 .05
-
Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
Cancer Research and Treatment
2023 .04
-
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Clinical and Molecular Hepatology
2024 .04
-
Implication of Pre- and Post-Radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study
Cancer Research and Treatment
2024 .04
-
Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
Investigative and Clinical Urology
2021 .01
-
Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue
Cancer Research and Treatment
2022 .01
-
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC
Cancer Research and Treatment
2024 .07
-
Secondary Germline CDKN2A Mutation Identified using Liquid Biopsy in a Patient with Esophageal Cancer
Laboratory Medicine Online
2022 .01
-
Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer
Cancer Research and Treatment
2020 .01
-
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
Cancer Research and Treatment
2022 .07
-
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
Gut and Liver
2019 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0